aspirin has been researched along with bosentan anhydrous in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Bishop, A; Crome, R; Duggan, AE; Filipowicz, B; Hawkey, CJ; Hull, M; Knifton, A; Polak, J; Stack, W; Weber, C | 1 |
| Burhop, K; Grose, JH; Harvey, N; Larivière, R; Lebel, M; Moisan, S; Rioux, F | 1 |
| Berkane, N; Blandin, V; Breittmayer, JP; Ferrari, E; Frelin, C; Talbodec, A; Vigne, P | 1 |
| Fischer, T | 1 |
2 review(s) available for aspirin and bosentan anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Pharmacological therapy of age-related macular degeneration based on etiopathogenesis].
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Aspirin; Bosentan; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infliximab; Lutein; Macular Degeneration; Melatonin; PPAR gamma; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Resveratrol; Stilbenes; Sulfonamides; Trimetazidine; Tumor Necrosis Factor-alpha; Ubiquinone; Vitamin D; Xanthophylls | 2015 |
1 trial(s) available for aspirin and bosentan anhydrous
| Article | Year |
|---|---|
Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bosentan; Cross-Over Studies; Dinoprostone; Double-Blind Method; Endothelin Receptor Antagonists; Gastric Mucosa; Humans; Male; Misoprostol; Receptor, Endothelin A; Sulfonamides | 1999 |
11 other study(ies) available for aspirin and bosentan anhydrous
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Nonpeptide endothelin receptor antagonists attenuate the pressor effect of diaspirin-crosslinked hemoglobin in rat.
Topics: Animals; Aspirin; Blood Pressure; Blood Substitutes; Bosentan; Endothelin Receptor Antagonists; Heart Rate; Hemoglobins; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phenylpropionates; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides | 1999 |
Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism.
Topics: Allosteric Regulation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Aspirin; Biological Transport; Bosentan; Calcium; Cells, Cultured; Drug Synergism; Endothelin Receptor Antagonists; Endothelin-1; Humans; Mammary Arteries; Muscle Contraction; Rats; Receptors, Endothelin; Sodium Salicylate; Sulfonamides | 2000 |